Patents Assigned to Essential Therapeutics, Inc.
-
Patent number: 6750038Abstract: This invention relates to a method for the rapidly determining the susceptibility of bacteria to antibiotics using histochemical detection of enzyme inhibition by the antibiotic.Type: GrantFiled: August 1, 2001Date of Patent: June 15, 2004Assignee: Essential Therapeutics, Inc.Inventor: Paul K. Nakane
-
Patent number: 6723716Abstract: The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.Type: GrantFiled: September 21, 2000Date of Patent: April 20, 2004Assignee: Essential Therapeutics, Inc.Inventors: Scott J. Hecker, Aesop Cho, Tomasz W. Glinka, Trevor Calkins, Ving J. Lee
-
Patent number: 6689782Abstract: This invention relates to compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism.Type: GrantFiled: December 30, 2002Date of Patent: February 10, 2004Assignee: Essential Therapeutics, Inc.Inventors: William J. Watkins, Remy Lemoine, Aesop Cho, Monica Palme
-
Patent number: 6638718Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 17, 2000Date of Patent: October 28, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6630303Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 17, 2000Date of Patent: October 7, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6599893Abstract: The present invention relates to chemical compounds having the formula: or a pharmaceutically acceptable salt thereof. R1 is selected from the group consisting of: R2 is selected from the group consisting of hydrogen, CH3—, FCH2—, F2CH— R3 is selected from the group consisting of: X is selected from the group consisting of hydrogen, halogen, cyano, —NH2, —N(CH3)2, —HSO2NH2, —SO2NH2 and —SCH3. The subscript n is 0 or 1.Type: GrantFiled: August 8, 2001Date of Patent: July 29, 2003Assignee: Essential Therapeutics, Inc.Inventor: Tomasz W. Glinka
-
Patent number: 6596723Abstract: This invention relates to compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism.Type: GrantFiled: July 16, 2001Date of Patent: July 22, 2003Assignee: Essential Therapeutics, Inc.Inventors: Will J. Watkins, Remy Lemoine, Aesop Cho, Thomas E. Renau
-
Patent number: 6551591Abstract: The present invention provides a novel strain of Microbispora corallina, means for identifying it, methods for culturing it at several different levels, two new antibiotics derived from the cultures and the physico-chemical characteristics of those compounds and their biological activity against a variety of microorganisms.Type: GrantFiled: September 7, 2001Date of Patent: April 22, 2003Assignee: Essential Therapeutics, Inc.Inventor: May D. Lee
-
Patent number: 6514746Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial genes which encode the components of a two-component regulatory pair. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: May 20, 1998Date of Patent: February 4, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6495591Abstract: The use of compounds of the milbemycin class as inhibitors of efflux pumps in microbes or other cells is described, along with pharmaceutical compositions incorporating a milbemycin. Also described is a method of screening for compounds which inhibit a CDR1, CDR2, BEN, or FLU1 efflux pump or a pump with components having a high level of protein level sequence similarity with the components of those efflux pumps.Type: GrantFiled: October 1, 1998Date of Patent: December 17, 2002Assignee: Essential Therapeutics, Inc.Inventors: Suzanne Chamberland, May Lee, Olga Lomovskaya
-
Patent number: 6482921Abstract: The present invention relates to dihydro derivatives of the uridyl peptide antibiotics mureidomycin, pacidimycin and napsamycin which have antibiotic activity against a number of bacterial strains including strains resistant to current therapeutic antibiotics.Type: GrantFiled: June 11, 1999Date of Patent: November 19, 2002Assignee: Essential Therapeutics, Inc.Inventors: Constantine G. Boojamra, Rémy C. Lemoine, Scott Hecker, Ving J. Lee, Roger Léger
-
Patent number: 6436980Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.Type: GrantFiled: November 28, 2000Date of Patent: August 20, 2002Assignee: Essential Therapeutics, Inc.Inventors: Roger Leger, Ving J. Lee, Miles She